Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer

The combination of docetaxel, trastuzumab, and pertuzumab (THP) is an established first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.

By Wang, Li, Xu +39The New England journal of medicineOct 24, 2026

Score█████░░░░░5.4

Key numbers

58.5% vs
95% confidence interval
87.6% in the anbenitamab group

VerdictA leading story on any desk.

Read the original

Abstract

Background The combination of docetaxel, trastuzumab, and pertuzumab (THP) is an established first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. The efficacy and safety of anbenitamab, a HER2-targeted bispecific antibody, plus albumin-bound docetaxel (HB1801) in this context are unknown. Methods In this phase 3, multicenter, open-label, randomized trial conducted in China, we randomly assigned patients with HER2-positive advanced breast cancer in a 1:1 ratio to receive either anbenitamab plus HB1801 or THP. The primary end point was progression-free survival, as assessed by blinded independent central review. Objective response was a secondary end point. Results A total of 885 patients were enrolled (445 were assigned to receive anbenitamab plus HB1801 and 440 to receive THP). At this prespecified interim analysis (with 401 events [disease progression or death] and a median follow-up of 21.0 months), the estimated 24-month progression-free survival was significantly higher with anbenitamab plus HB1801 than with THP (58.5% vs. 34.4%; hazard ratio for progression or death, 0.46; 95% confidence interval, 0.37 to 0.56; P<0.001). The percentage of patients with an objective response was 87.6% in the anbenitamab group and 73.4% in the THP group. Adverse events of grade 3 or higher occurred in 204 of 444 patients (45.9%) in the anbenitamab group and in 151 of 439 patients (34.4%) in the THP group. Neutropenia was the most common adverse event of grade 3 or higher in both groups (13.1% in the anbenitamab group and 8.4% in the THP group). Adverse events leading to death occurred in 2 patients in each group. Conclusions Anbenitamab plus HB1801 led to significantly higher progression-free survival than THP among patients with HER2-positive advanced breast cancer. (Funded by Shanghai JMT-Bio Technology and others; HEALER ClinicalTrials.gov number, NCT05838066.).

Jiayu Wang, Huiping Li, Fei Xu, Tao Wu, Zhongsheng Tong, Jiuwei Cui, Xujuan Wang, Zhenchuan Song, Tao Sun, Huihui Li, Weimin Xie, Jing Sun, Xueying Zhang, Yuee Teng, Xiaoping Li, Jinhai Zhu, Ting Luo, Bing Zhao, Fangling Ning, Chunwei Xie, Lu Gan, Guobing Yin, Yang Li, Chunxiu Yuan, Wei You, Zhiyong Wu, Qiang Liu, Xiangshun Kong, Jianying Chang, Jiuda Zhao, et al.

The editor's rubric

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 10% of this desk’s rubric
Magnitude4 / 5: A qualitative jump: a capability or regime that did not exist before.; 20% of this desk’s rubric
Evidence5 / 5: Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.; 32% of this desk’s rubric
Novelty3 / 5: A genuinely new approach to an open problem.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░2/5	10%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	████░4/5	20%	A qualitative jump: a capability or regime that did not exist before.
Evidence	█████5/5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	███░░3/5	8%	A genuinely new approach to an open problem.
Trajectory	██░░░2/5	5%	Some room to improve with obvious engineering.
Stakes	███░░3/5	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (versus baseline, efficacy); design (randomized, blinded, phase 3); verification (confidence interval, p-value); stakes (mortality, major disease, prevention or cure).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.4

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 7.4 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.7 / 10; Shrunk toward the desk prior by editor confidence (50%).
Attention: 4%; Citations, upvotes, points, mentions.
Freshness: 80%; Half-life decay since publication.

Citations1 (reference 20, via openalex, Oct 27, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v10 on Oct 27, 2026, 06:17 UTC. Paper type: clinical.
Categories: Journal Article
TOP, No.1 in the Medicine edition of October 27, 2026.